Sign In

Login

Password

Forgot Password ? Sign Up

Pyrazinamide (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Pyrazinamide" in French language version.

refsWebsite
Global rank French rank
8nih.gov
4th place
12th place
5doi.org
2nd place
3rd place
3sciencedirect.com
149th place
80th place
1qmul.ac.uk
1,735th place
168th place
1who.int
195th place
221st place
1cdc.gov
218th place
480th place
1atsjournals.org
low place
4,703rd place
1ingenta.com
low place
low place

atsjournals.org

  • (en) D Yee, C Valiquette, M Pelletier, I Parisien, I Rocher et Dick Menzies, « Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis », American Journal of Respiratory and Critical Care Medicine, vol. 167, no 11,‎ , p. 1472-1477. (PMID 12569078, DOI 10.1164/rccm.200206-626OC, lire en ligne)

cdc.gov

  • (en) « Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. », MMWR Recommendations and Reports, vol. 49, no RR-6,‎ , p. 1-51 (PMID 10881762, lire en ligne)

doi.org

dx.doi.org

  • (en) « Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis », The Lancet, vol. 1, no 8213,‎ , p. 171-174 (PMID 6109855, DOI 10.1016/S0140-6736(02)95623-0, lire en ligne)
  • (en) East and Central African/British Medical Research Council Fifth Collaborative Study, « Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis », Tubercle, vol. 64, no 3,‎ , p. 153-166 (PMID 6356538, DOI 10.1016/0041-3879(83)90011-9, lire en ligne)
  • (en) British Thoracic Society, « A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis Final report: Results during the 36 months after the end of chemotherapy and beyond », British Journal of Diseases of the Chest, vol. 78,‎ , p. 330-336. (PMID 6386028, DOI 10.1016/0007-0971(84)90165-7, lire en ligne)
  • (en) D Yee, C Valiquette, M Pelletier, I Parisien, I Rocher et Dick Menzies, « Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis », American Journal of Respiratory and Critical Care Medicine, vol. 167, no 11,‎ , p. 1472-1477. (PMID 12569078, DOI 10.1164/rccm.200206-626OC, lire en ligne)
  • (en) W Shi, X Zhang, X Jiang, H Yuan, JS Lee, CE Barry, H Wang, W Zhang et Y Zhang, « Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis: a potential mechanism for shortening the duration of tuberculosis chemotherapy », Science, vol. 333, no 6049,‎ , p. 1630-1632 (PMID 21835980, PMCID 3502614, DOI 10.1126/science.1208813)

ingenta.com

openurl.ingenta.com

  • (en) Y Zhang et D Mitchison, « The curious characteristics of pyrazinamide: a review », Int. J. Tuberc. Lung Dis., vol. 7, no 1,‎ , p. 6-21 (PMID 12701830, lire en ligne)

nih.gov

ncbi.nlm.nih.gov

  • (en) « Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis », The Lancet, vol. 1, no 8213,‎ , p. 171-174 (PMID 6109855, DOI 10.1016/S0140-6736(02)95623-0, lire en ligne)
  • (en) « Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. », MMWR Recommendations and Reports, vol. 49, no RR-6,‎ , p. 1-51 (PMID 10881762, lire en ligne)
  • (en) East and Central African/British Medical Research Council Fifth Collaborative Study, « Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis », Tubercle, vol. 64, no 3,‎ , p. 153-166 (PMID 6356538, DOI 10.1016/0041-3879(83)90011-9, lire en ligne)
  • (en) British Thoracic Society, « A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis Final report: Results during the 36 months after the end of chemotherapy and beyond », British Journal of Diseases of the Chest, vol. 78,‎ , p. 330-336. (PMID 6386028, DOI 10.1016/0007-0971(84)90165-7, lire en ligne)
  • (en) D Yee, C Valiquette, M Pelletier, I Parisien, I Rocher et Dick Menzies, « Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis », American Journal of Respiratory and Critical Care Medicine, vol. 167, no 11,‎ , p. 1472-1477. (PMID 12569078, DOI 10.1164/rccm.200206-626OC, lire en ligne)
  • (en) Y Zhang et D Mitchison, « The curious characteristics of pyrazinamide: a review », Int. J. Tuberc. Lung Dis., vol. 7, no 1,‎ , p. 6-21 (PMID 12701830, lire en ligne)
  • (en) O Zimhony, JS Cox, JT Welch, C Vilchèze et WR Jacobs, « Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. », Nature Medecine, vol. 6, no 9,‎ , p. 1043-1047 (PMID 10973326)
  • (en) W Shi, X Zhang, X Jiang, H Yuan, JS Lee, CE Barry, H Wang, W Zhang et Y Zhang, « Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis: a potential mechanism for shortening the duration of tuberculosis chemotherapy », Science, vol. 333, no 6049,‎ , p. 1630-1632 (PMID 21835980, PMCID 3502614, DOI 10.1126/science.1208813)

qmul.ac.uk

chem.qmul.ac.uk

sciencedirect.com

  • (en) « Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis », The Lancet, vol. 1, no 8213,‎ , p. 171-174 (PMID 6109855, DOI 10.1016/S0140-6736(02)95623-0, lire en ligne)
  • (en) East and Central African/British Medical Research Council Fifth Collaborative Study, « Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis », Tubercle, vol. 64, no 3,‎ , p. 153-166 (PMID 6356538, DOI 10.1016/0041-3879(83)90011-9, lire en ligne)
  • (en) British Thoracic Society, « A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis Final report: Results during the 36 months after the end of chemotherapy and beyond », British Journal of Diseases of the Chest, vol. 78,‎ , p. 330-336. (PMID 6386028, DOI 10.1016/0007-0971(84)90165-7, lire en ligne)

who.int